FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder.
Cancer Res
; 63(23): 8108-12, 2003 Dec 01.
Article
in En
| MEDLINE
| ID: mdl-14678961
ABSTRACT
FGFR3 and TP53 mutations are frequent in superficial papillary and invasive disease, respectively. We used denaturing high-performance liquid chromatography and sequencing to screen for FGFR3 and TP53 mutations in 81 newly diagnosed urothelial cell carcinomas. Tumors were classified as follows 31 pTa, 1 carcinoma in situ, 30 pT1, and 19 pT2-T4. Tumor grades were as follows 10 G1, 29 G2, and 42 G3. FGFR3 mutations were associated with low-stage (P < 0.0001), low-grade (P < 0.008) tumors, whereas TP53 mutations were associated with high-stage (P < 0.003), high-grade (P < 0.02) tumors. Mutations in these two genes were almost mutually exclusive. Our results suggest that FGFR3 and TP53 mutations define separate pathways at initial diagnosis of urothelial cell carcinoma.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Urinary Bladder Neoplasms
/
Protein-Tyrosine Kinases
/
Carcinoma, Transitional Cell
/
Genes, p53
/
Receptors, Fibroblast Growth Factor
/
Mutation
Limits:
Adult
/
Aged
/
Aged80
/
Humans
/
Middle aged
Language:
En
Journal:
Cancer Res
Year:
2003
Document type:
Article
Affiliation country:
Francia